<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00027911</url>
  </required_header>
  <id_info>
    <org_study_id>AAAB2273</org_study_id>
    <secondary_id>CPMC-IRB-13578</secondary_id>
    <secondary_id>LUDWIG-LUD00-024</secondary_id>
    <secondary_id>NCI-G01-2035</secondary_id>
    <nct_id>NCT00027911</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma</brief_title>
  <official_title>A Pilot Study of NY-ESO-1 Immunization in Patients With NY-ESO-1/LAGE Antigen Expressing Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.&#xD;
      Colony-stimulating factors such as sargramostim increase the number of immune cells found in&#xD;
      bone marrow or peripheral blood. Combining vaccine therapy with sargramostim may be effective&#xD;
      in treating soft tissue sarcoma.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining vaccine therapy with&#xD;
      sargramostim in treating patients who have stage II, stage III, or stage IV soft tissue&#xD;
      sarcoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and tolerability of NY-ESO-1 peptide vaccine and sargramostim&#xD;
           (GM-CSF) in patients with stage II, III, or IV soft tissue sarcoma expressing NY-ESO-1&#xD;
           or LAGE antigen.&#xD;
&#xD;
        -  Determine the immunologic profile (NY-ESO-1 antibody, CD8+ cells, and delayed-type&#xD;
           hypersensitivity) in patients treated with this regimen.&#xD;
&#xD;
        -  Determine tumor responses in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: Patients receive NY-ESO-1 peptide vaccine intradermally once every 2 weeks for a&#xD;
      total of 6 vaccinations. Patients also receive sargramostim (GM-CSF) subcutaneously once&#xD;
      daily beginning 2 days before every vaccination and continuing for 5 days. Treatment&#xD;
      continues in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15 patients will be accrued for this study within 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Departure of PI&#xD;
  </why_stopped>
  <start_date>April 2001</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NY-ESO-1 peptide vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed high-risk stage II, III, or IV soft tissue sarcoma expressing&#xD;
             NY-ESO-1 or LAGE antigen (including, but not limited to, synovial sarcoma)&#xD;
&#xD;
          -  HLA-A2 allele for NY-ESO-1 peptides&#xD;
&#xD;
          -  Declined, failed, or completed standard therapy&#xD;
&#xD;
          -  CNS metastases allowed if treated and stable&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Hemoglobin at least 9.0 g/dL&#xD;
&#xD;
          -  Lymphocyte count at least 500/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
          -  No bleeding disorders&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2 mg/dL&#xD;
&#xD;
          -  Hepatitis B and C negative&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.8 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other serious illness (e.g., serious infection requiring antibiotics)&#xD;
&#xD;
          -  No immunodeficiency disease&#xD;
&#xD;
          -  No psychiatric or addictive disorders that would preclude study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior bone marrow or peripheral blood stem cell transplantation&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent steroids except topical or inhaled steroids&#xD;
&#xD;
          -  Concurrent noncytotoxic anticancer hormonal therapy allowed (e.g., hormones for breast&#xD;
             or prostate cancer)&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 4 weeks since prior surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 4 weeks since prior participation in any other clinical trial involving&#xD;
             another investigational agent&#xD;
&#xD;
          -  No concurrent antihistamines&#xD;
&#xD;
          -  No concurrent non-steroidal anti-inflammatory drugs except low doses for prevention of&#xD;
             an acute cardiovascular event or pain control&#xD;
&#xD;
          -  No concurrent immunosuppressive agents&#xD;
&#xD;
          -  Concurrent noncytotoxic anticancer therapy allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyriakos P. Papadopoulos, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Herbert Irving Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>December 7, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 13, 2013</last_update_submitted>
  <last_update_submitted_qc>February 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult synovial sarcoma</keyword>
  <keyword>stage III adult soft tissue sarcoma</keyword>
  <keyword>recurrent adult soft tissue sarcoma</keyword>
  <keyword>stage IV adult soft tissue sarcoma</keyword>
  <keyword>stage II adult soft tissue sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

